X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (137) 137
hygiene (137) 137
medical or veterinary science (137) 137
preparations for medical, dental, or toilet purposes (135) 135
chemistry (121) 121
metallurgy (121) 121
organic chemistry (114) 114
specific therapeutic activity of chemical compounds ormedicinal preparations (88) 88
heterocyclic compounds (78) 78
microbiology (61) 61
humans (52) 52
index medicus (44) 44
beer (43) 43
biochemistry (43) 43
compositions thereof (43) 43
culture media (43) 43
enzymology (43) 43
microorganisms or enzymes (43) 43
mutation or genetic engineering (43) 43
propagating, preserving or maintaining microorganisms (43) 43
spirits (43) 43
vinegar (43) 43
wine (43) 43
peptides (39) 39
compositions or test papers therefor (32) 32
condition-responsive control in microbiological orenzymological processes (32) 32
investigating or analysing materials by determining theirchemical or physical properties (32) 32
measuring (32) 32
measuring or testing processes involving enzymes, nucleicacids or microorganisms (32) 32
physics (32) 32
processes of preparing such compositions (32) 32
testing (32) 32
hepacivirus - genetics (30) 30
hepatitis (29) 29
ribavirin (29) 29
general tagging of cross-sectional technologies spanning over several sections of the ipc (28) 28
general tagging of new technological developments (28) 28
hepatitis c (28) 28
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (28) 28
hcv (27) 27
hepatitis c virus (25) 25
antiviral agents (24) 24
technical subjects covered by former uspc (24) 24
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (24) 24
genotype (23) 23
hepacivirus - drug effects (21) 21
genetic aspects (19) 19
interferon (19) 19
antiviral agents - therapeutic use (18) 18
female (18) 18
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (18) 18
gastroenterology & hepatology (18) 18
male (18) 18
pharmacology & pharmacy (18) 18
genotypes (17) 17
middle aged (17) 17
nucleic acids (17) 17
virology (17) 17
virus diseases (17) 17
viruses (17) 17
drug therapy, combination (16) 16
hepatitis c, chronic - drug therapy (16) 16
molecular sequence data (16) 16
derivatives thereof (15) 15
nucleosides (15) 15
nucleotides (15) 15
patients (15) 15
processes using microorganisms (15) 15
sugars (15) 15
cirrhosis (14) 14
in-vitro (14) 14
sofosbuvir (14) 14
viral nonstructural proteins - antagonists & inhibitors (14) 14
adult (13) 13
aged (13) 13
anilides - therapeutic use (12) 12
carbamates - therapeutic use (12) 12
gastroenterology and hepatology (12) 12
infections (12) 12
liver cirrhosis (12) 12
ritonavir (12) 12
abt-450/r-ombitasvir (11) 11
antiviral agents - adverse effects (11) 11
antiviral agents - pharmacology (11) 11
base sequence (11) 11
health aspects (11) 11
macrocyclic compounds - therapeutic use (11) 11
abridged index medicus (10) 10
amino acid sequence (10) 10
animals (10) 10
biochemical phenomena, metabolism, and nutrition (10) 10
drug therapy (10) 10
genotype & phenotype (10) 10
hepatitis c, chronic - virology (10) 10
pibrentasvir (10) 10
ritonavir - therapeutic use (10) 10
viral nonstructural proteins - genetics (10) 10
amino acids (9) 9
analysis (9) 9
anilides - adverse effects (9) 9
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (291) 291
French (62) 62
German (26) 26
Chinese (19) 19
Spanish (9) 9
Portuguese (6) 6
Japanese (2) 2
Korean (2) 2
Danish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Hepatology, ISSN 0270-9139, 02/2018, Volume 67, Issue 2, pp. 514 - 523
This study assessed the efficacy and safety of ribavirin‐free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3... 
NATURAL PREVALENCE | FIBROSIS | VELPATASVIR | STEATOSIS | SOFOSBUVIR | RESISTANCE | HCV GENOTYPE | INFECTION | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | PROGRESSION | Cirrhosis | Hepatitis | Clinical trials | Interferon | Hepatitis C | Patients | Ribavirin | Genotypes | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 566 - 575
Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic... 
Pibrentasvir | Cirrhosis | Medicine & Public Health | Glecaprevir | Colorectal Surgery | Hepatology | Gastroenterology | Renal failure | Abdominal Surgery | Special population | Surgical Oncology | PLUS RIBAVIRIN | SOFOSBUVIR | CHRONIC HEPATITIS-C | OPEN-LABEL | TREATMENT-NAIVE | PHASE-3 TRIAL | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Young Adult | Treatment Failure | Adult | Female | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Medical research | Protease inhibitors | Proteases | Analysis | Medicine, Experimental | Genetic aspects | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis | Kidneys | Hemodialysis | Oral administration | Chronic infection | Interferon | Ribonucleic acid--RNA | Patients | Glomerular filtration rate | Kidney transplantation | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Hepatology, ISSN 0270-9139, 02/2018, Volume 67, Issue 2, pp. 505 - 513
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once‐daily, all oral,... 
ASIA | SOFOSBUVIR | CIRRHOSIS | PHASE-3 TRIAL | PREVALENCE | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | Cirrhosis | Antiretroviral drugs | Hepatitis | Chronic infection | Infections | Interferon | Safety | Hepatitis C | Patients | Ribavirin | Genotypes | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 45 - 53
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 222 - 232
In this phase 2 study, peginterferon-free regimens were effective in patients with hepatitis C virus genotype 1 infection. Chronic hepatitis C virus (HCV)... 
MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | TELAPREVIR | BOCEPREVIR | INHIBITOR | HCV INFECTION | ASSOCIATION | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Young Adult | Adult | Female | Drug Therapy, Combination |